Spectral total variation’s ability to provide metrics for the automatic detection of bone malignant lesions and to differentiate those lesions from non-cancerous findings will be assessed for a hybrid positron emission tomography/x-ray computed tomography (PET/CT) scanner. By detecting tissue metabolism changes using fluorine-18-2-fluoro-2-deoxy-D-glucose PET and demonstrating bone structure changes using CT, PET/CT can identify cancer lesions and impact patient diagnosis and management.
